In a randomised , multicentre , double-blind phase 3 trial in 134 centres in 23 countries , we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer , progression after one or two previous regimens of chemotherapy , Eastern Cooperative Oncology Group ( ECOG ) performance status of 0-2 , and presence of measurable disease .